STARPHARMA HOLDINGS LTD.

WKN
796461
ISIN
AU000000SPL0
  • Equities
  • Equities international
An error occured while loading the chart data.

0.780 EUR Sell

0.800 EUR Buy

+0.03 abs.

+4.3 % rel.

2019-11-11 08:40 pmLang & Schwarz
  • Close / Open 0.758 / 0.758
  • High / Low (1 day) 0.800 / 0.755
  • High / Low (1 Year) 1.039 / 0.600
  • 1 Week +7.5 %
  • 1 Month +10.5 %
  • 1 Year -23.6 %

Selected Top-Trade

There are no top-trades for this security.

Popularity indicator

An error occured while loading the chart data.

Trading sentiment

An error occured while loading the chart data.

Latest Comments

Starpharma Holdings Limited is a world leader in the development of dendrimer products for pharmaceutical, life-science and other applications. Starpharma’s lead products are based on VivaGel ® (SPL7013, astodrimer sodium), a proprietary dendrimer which has antimicrobial properties. VivaGel® formulated as a water based gel and delivered vaginally now has EU regulatory approval for topical treatment and rapid relief of bacterial vaginosis (BV) and is under clinical development for the prevention of recurrent BV. Starpharma has also signed separate licence agreements with Ansell Limited and Okamoto Industries. Inc., to market a value-added, VivaGel® condom. The VivaGel® condom is available for purchase in Australia under Ansell’s Lifestyles® Dual Protect TM brand. In the wider pharmaceutical field, Starpharma has both partnered and internal programs in Drug Delivery. A number of dendrimer-enhanced, or DEP® versions of existing drugs are under development. The most advanced of these is DEP® docetaxel, a dendrimer-enhanced version of docetaxel (Taxotere®), which is in clinical development in patients with solid tumours. In preclinical studies DEP® docetaxel has shown significant tumour-targeting and superior anti-cancer effects across a range of important cancer types including breast, prostate, lung and ovarian tumour, when compared to Taxotere® (docetaxel). AstraZeneca has signed a licensing agreement with Starpharma for the use of its DEP® drug delivery platform in the development and commercialisation of an AstraZeneca oncology compound, with potential for follow on compounds directed at a defined family of targets. In agrochemicals Starpharma has a series of partnerships with leading industry players including global leader Adama (formerly Makhteshim Agan) as well as internal programs including an enhanced version of glyphosate.
show more
Don't miss out on anything!
To see all comments of this underlying please create an account.